Abstract
Juvenile idiopathic arthritis (JIA) encompasses a heterogeneous group of chronic arthritis of unknown origin that appear before 16 years of age and persist for more than six weeks, once other causes are excluded. They are characterized by the presence of joint inflammation and are accompanied to a greater or lesser extent by systematic manifestations. It is the most frequent chronic inflammatory rheumatic disease in childhood. The currently accepted classification groups are those described by the International League of Associations for Rheumatology (ILAR). However, new modifications to these criteria have recently been proposed. JIA has a multifactorial etiopathogenesis, immunological mechanisms, and environmental mechanisms that act on a genetically predisposed individual. Except for the systemic JIA subtype, which has an autoinflammatory basis, the remaining JIA forms have a clear autoimmune component. Early diagnosis and adequate treatment are crucial for avoiding complications. This treatment must be individualized based on clinical manifestations and the degree of organ involvement. In addition to glucocorticoids and synthetic disease-modifying drugs (DMDs), the prognosis of JIA has notably improved since the introduction of biological DMDs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
